Solís-Martínez RA, Gómez-Mar SG, Solís-Novelo A, Silos- Rodríguez H, Vázquez-Castillo TV

Language: Spanish
References: 21
Page: 94-100
PDF size: 715.88 Kb.

ABSTRACT

Sepsis represents a continuum disease due to systemic inflammatory response caused by chronic infection. Sepsis is a significant cause of death worldwide and represents a serious problem in trauma. In recent years, many efforts have been made to improve the understanding of the deregulation of the host response in this disease, as a result, much has been learned from the underlying pathophysiological mechanisms, enabling new and better opportunities for early diagnosis and favoring timely therapeutic intervention. This review article focuses on the mechanisms and molecular components involved in the pathogenesis and various biomarkers of existing utility in the clinical management of sepsis.

REFERENCES

1. Hawiger J, Veach R.A. and Zienkiewicz J. New paradigms in sepsis: from prevention to protection of failing microcirculation. J Thrombosis Haemostasis. 2015;13:1743-1756.

2. Wang H and Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med. 2008;26:711-715.

3. Dewar DC and Balogh ZJ. The epidemiology of multiple-organ failure: a definition controversy. Acta Anaesthesiol Scand. 2011;55:248-249.

4. 4 .World Health Organization. Repositorio Institucional para Compartir Información. Disponible en: http://apps.who.int/iris/bitstream/10665/82218/ 1/9789243564586_spa.pdf.

5. Martín-Ramírez JF, Domínguez-Borgua A and Vázquez-Flores D. Sepsis. Med. Int. Mex. 2014;30:159-75.

6. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-74.

7. Mayr FB, Yende S and Angus DC. Epidemiology of severe sepsis. Virulence. 2014;5:1,4–11.

8. Derek C. Angus, and Tom van der Poll. Severe Sepsis and Septic Shock. NEJM. 2013;369:840-51.

9. Kaukonen J, Bailey M, Pilcher D, Cooper J and Bellomo R. Systemic Inflammatory Response Syndrome Criteria in Defining Severe Sepsis. N Engl J Med.2015;372(17):1629-38.

10. Mayr FB, Yende S, and Angus DC. Epidemiology of severe sepsis. Virulence. 2014;5:(1):4–11.

11. Martin GS. Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. Expert Rev Anti Infect Ther. 2012;10(6):701–706.

12. Pawlinski N and Mackman N. Cellular Sources of Tissue Factor in Endotoxemia and Sepsis. Thromb Res. 2010;125 S1:S70–S73.

13. 13.Garrean S, Gao XP, Brovkovych V, Shimizu J, Zhao YY, Vogel SM, Malik AB. Caveolin-1 regulates NFkappaB activation and lung inflammatory response to sepsis induced by lipopolysaccharide. J Immunol. 2006;177(7):4853-60.

14. Qureshi K and Rajah A.Septic Shock: Clinical Microbiology Reviews. BJMP. 2008;1(2):7-12.

15. Hotchkiss RS, Monneret G and Payen D. Sepsisinduced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862-74.

16. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ; ACCP/SCCM. Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. TheACCP/SCCM Consensus Conference Committee. American Collegeof Chest Physicians/Society of Critical Care Medicine. 1992. Chest. 2009;136(5):e28.

17. Faix JD. Biomarkers of sepsis. Crit Rev Clin Lab Sci. 2013;50(1):23–36.

18. Mouncey P, Tiffany M, Osborn & et al. Trial of Early, Goal-Directed Resuscitation for Septic Shock. N Engl J Med. 2015; 372:1301-1311.

19. Briceño I. Sepsis: Tratamiento. MEDICRIT. 2006;3(1):1–13.

20. Pierrakos CH and Vincent JL. Sepsis biomarkers: a review. Critical Care. 2010;14:R15.

21. Konrad Reinhart,a Michael Bauer,a,b Niels C. Riedemann,a and Christiane S. HartogaNew Approaches to Sepsis: Molecular Diagnostics and Biomar kers. Clinical Microbiology Reviews. 2012;25(4):609–63.